Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

被引：0
|
作者：
Chen, K. [1 ]
Yu, X. [1 ]
Wang, H. [1 ]
Huang, Z. [2 ]
Xu, Y. [2 ]
Gong, L. [2 ]
Fan, Y. [2 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Canc Hosp, Chemotherapy, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Epidermal growth factor receptor; uncommon mutation; Tyrosine kinase inhibitors;
D O I：
10.1016/j.jtho.2017.09.305
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.03-013
引用
收藏
页码：S2131 / S2131
页数：1
相关论文
共 50 条
  • [1] Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
    Chen, Kaiyan
    Yu, Xiaoqing
    Wang, Haiyang
    Huang, Zhiyu
    Xu, Yanjun
    Gong, Lei
    Fan, Yun
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1179 - 1187
  • [2] Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
    Kaiyan Chen
    Xiaoqing Yu
    Haiyang Wang
    Zhiyu Huang
    Yanjun Xu
    Lei Gong
    Yun Fan
    [J]. Cancer Chemotherapy and Pharmacology, 2017, 80 : 1179 - 1187
  • [3] Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer
    Hunter, S.
    Nickless, G.
    Ghosh, S.
    Lal, R.
    Merrick, S. A.
    Montes, A.
    Smith, D.
    Spicer, J.
    Karapanagiotou, E.
    [J]. LUNG CANCER, 2017, 103 : S34 - S35
  • [4] Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
    Maevskaya, J.
    Laktionov, K.
    Yudin, D.
    Vladimirova, L.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1402 - S1402
  • [5] EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
    Xiuning Le
    Eric Nadler
    Daniel B. Costa
    John Victor Heymach
    [J]. Targeted Oncology, 2023, 18 : 807 - 817
  • [6] EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
    Le, Xiuning
    Nadler, Eric
    Costa, Daniel B.
    Heymach, John Victor
    [J]. TARGETED ONCOLOGY, 2023, 18 (06) : 807 - 817
  • [7] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    [J]. ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [8] Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
    Kanazu, Masaki
    Mori, Masahide
    Kimura, Madoka
    Nishino, Kazumi
    Shiroyama, Takayuki
    Nagatomo, Izumi
    Ihara, Shoichi
    Komuta, Kiyoshi
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Kumagai, Toru
    Imamura, Fumio
    [J]. THORACIC CANCER, 2021, 12 (01) : 90 - 96
  • [9] Uncommon mutation types of Epidermal Growth Factor Receptor (EGFR) and tyrosine kinase inhibitor response in non-small cell lung carcinoma
    Wong, Maria P.
    Lee, Victor H. F.
    Yeung, Rebecca M. W.
    Tin, Vicky P. C.
    Choy, Kit Chi
    Liu, Jing
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [10] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Roviello, Giandomenico
    Zanotti, Laura
    Cappelletti, Maria Rosa
    Gobbi, Angela
    Dester, Martina
    Paganini, Giovanni
    Pacifico, Chiara
    Generali, Daniele
    Roudi, Raheleh
    [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 18 (01) : 15 - 20
12345